Danaher picks up U.K. data analytics player to boost drug development offerings

Danaher has four major divisions: environmental and applied solutions, dental, diagnostics and life sciences, after spinning off its industrial businesses as Fortive last year.

Danaher has acquired IDBS, a U.K.-based scientific informatics company, to round out its life sciences portfolio. The company hopes that IDBS’ data management, analytics and modeling platforms will accelerate the pace of drug discovery and development.

Danaher’s businesses span environmental and applied solutions, dental, diagnostics and life sciences. IDBS will join companies such as Beckman Coulter Life Sciences and Molecular Devices, both of which make scientific instruments for research and drug discovery.

“IDBS’ informatics solutions integrate insights derived using scientific instruments from various vendors and from many different disciplines, enabling better and faster scientific and business decisions ultimately affording patients faster and better therapies,” said Rainer Blair, Danaher executive vice president, in the statement. “IDBS opens a new generation of vendor agnostic information-based digital services for Danaher and makes the digital lab a reality.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“By linking the IDBS knowledge management platform with their comprehensive instrument coverage it will create a ‘data spine’ that connects instruments, creating opportunities for new information-based services and the realization of the digital lab of the future,” said IDBS CEO Neil Kipling.

Danaher’s most recent acquisition was the diagnostics maker Cepheid, announced in September and closed in November last year. It followed a $13.1 billion deal to pick up Pall Corporation in May and a $30 million buyout of Applied Spectral Imaging in 2015.

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.